1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Sobi to sell Auxilium's Xiaflex in 71 countries

 
• By Sukaina Virji

Swedish Orphan Biovitrum (Sobi) has obtained exclusive rights in 71 countries for Auxilium Pharmaceuticals' first-in-class biologic Xiapex (collagenase clostridium histolyticum, known as Xiaflex in the US). The product was previously the subject of a collaboration agreement between Auxilium and Pfizer.

Swedish Orphan Biovitrum (Sobi) has obtained exclusive rights in 71 countries for Auxilium Pharmaceuticals' first-in-class biologic Xiapex (collagenase clostridium histolyticum, known as Xiaflex in the US). The product was previously the subject of a collaboration agreement between Auxilium and Pfizer.

In December 2008, Pfizer paid Auxilium $75m upfront for the rights to Xiapex in the EU, certain other European countries,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

AbbVie Makes Big Autoimmune CAR-T Play With Capstan Acquisition

 
• By Alaric DeArment

The drugmaker will spend up to $2.1bn to acquire the privately held biotech firm and its targeted lipid nanoparticle technology platform, with an anti-CD19 asset in the clinic.

More from Therapy Areas

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 
• By Alaric DeArment

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 
• By Andrew McConaghie and Edwin Elmhirst

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

In Brief: Nanoscope Ploughs Forward With FDA Application For Retinitis Pigmentosa Gene Therapy

 
• By Manas Mishra

Nanoscope’s experimental gene therapy, MCO-010, is designed to target the broader retinitis pigmentosa population, regardless of the underlying gene mutation, with a completed US regulatory submission expected in early 2026.